Clinical Study
Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients

Tarek M. Owaidah, Hazzaa A. Alzahrani, Nouf S. Al-Numair, Abdulmjeed O. Alnosair, Amelita M. Aguilos, and Mahasen Saleh

Departments of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Departments of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Departments of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Pediatric Hematology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Correspondence should be addressed to Tarek M. Owaidah; towaidah@kfshrc.edu.sa

Received 21 April 2020; Revised 25 June 2020; Accepted 15 July 2020; Published 9 September 2020

Background. The one-stage assay is the most common method to measure factor VIII activity (FVIII:C) in hemophilia A patients. The chromogenic assay is another two-stage test involving purified coagulation factors followed by factor Xa-specific chromogenic substrate. Aim. This study aimed to assess the discrepancy and correlation between the chromogenic and one-stage assays in measuring FVIII:C levels in hemophilia patients receiving Extended Half-Life Elocta® as a recombinant extended half-life coagulation factor. Methods. We performed a study comparing the measurements of FVIII:C levels by the chromogenic versus the one-stage assays at different drug levels. Data of FVIII:C levels, dosage, and the time interval from administration to measurement were retrieved from the hospital records. The correlation, mean differences, and discrepancy between the two assays were calculated. The linear regression analysis was used to predict the time interval till reaching 1% FVIII:C. Results. Fourteen patients with 56 samples were included in the study. Of them, 13 patients were receiving Elocta® as a prophylactic, while one was receiving Elocta® on demand. One-third of these samples showed a discrepancy between the chromogenic and one-stage assays. The two assays were well correlated. Mean differences were significant at the individual and the time interval level. The time since the last Elocta® injection could significantly predict FVIII:C levels ($\beta = 0.366, P < 0.001$). Conclusion. Our findings suggested a significant difference between both methods; the FVIII:C levels measured by the one-stage assay were less than those estimated by the chromogenic assay. However, the measurements of FVIII:C by the two assays were well correlated but discrepant in one-third of the samples. The levels of FVIII:C reach 1% after 5.4 days since the last Elocta® administration.

1. Introduction

Hemophilia A is an X-linked bleeding disorder caused by mutations in the genes for factor VIII (FVIII), affecting about one case per 5000 living male births [1–3]. Patients with mild hemophilia suffer from easy bleeding from external orifices and internal organs, especially with trauma or surgery. In moderate cases, patients tend to bleed after minor injuries; incidents of spontaneous bleeding without an apparent cause may occur, while those with severe hemophilia suffer from frequent, excessive, and spontaneous bleeding since birth [1–5]. The diagnosis of hemophilia is usually based on the clinical symptoms and laboratory analysis, confirming the deficiency of one of the coagulation factors. The severity of hemophilia depends on the extent of coagulation factor deficiency [6, 7]. Depending on the ratio of FVIII clotting protein in the blood, hemophilia had been classified to mild when FVIII is 6–49%, moderate when it is 1–5%, and severe if less than 1% [8, 9]. People with hemophilia A bleed longer than others, internally or externally.
Current treatment options for hemophilia A include factor replacement therapy and nonfactor replacement. The standard of care for patients with hemophilia A is prophylactic FVIII concentrate administration as replacement therapy to compensate for FVIII deficiency [10]. However, up to 30% of patients with severe hemophilia A may develop inhibitor antibodies [11, 12]. Therefore, those patients do not respond optimally to FVIII concentrate administration. In such cases, there are many treatment strategies, such as bypassing agents, high-dose clotting factor concentrates, or Immune Tolerance Induction (ITI) therapy [13].

A crucial step in the management of hemophilia A patients is the continuous monitoring of FVIII:C to avoid the severe decrease in FVIII:C, which might lead to spontaneous bleeding and hemorrhage. Therefore, laboratory testing in hemophilia patients is not only crucial for the diagnosis and the assessment of disease severity but also for monitoring and optimizing the treatment [14].

Recently, personalizing FVIII prophylaxis has been proposed to optimize the required treatment dose according to the individual pharmacokinetic response to FVIII [15, 16]. However, other factors as the types of FVIII assay and the FVIII product used still account for variations among patients and the different samples taken from the same patient [17]. The one-stage assay is the most commonly used method to measure FVIII:C. However, the chromogenic assay is a two-stage test that includes purified coagulation factors followed by a factor Xa-specific chromogenic substrate in the last stage [18]. The disadvantages of the one-stage assay include (1) the need for factor-deficient plasma, (2) the poor reproducibility, and (3) the relatively large reagent variability, while the disadvantages of the chromogenic assay include the high cost of the assay and the unfamiliarity in clinical practice [19].

The literature suggests that some discrepancies exist between the chromogenic and the one-stage assay for the measurements of FVIII:C levels in patients with mild and moderate hemophilia A [18, 20, 21]. In this study, we aimed to assess the discrepancy and correlation between the chromogenic and the one-stage assay in the measurement of FVIII:C levels in hemophilia patients who are receiving Elocta® as a recombinant extended half-life coagulation factor product.

2. Methods

We followed the “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE) statement guidelines when reporting this manuscript [22].

2.1. Study Design, Setting, and Duration. This is a case study of hemophilia A patients attending hemophilia clinics in King Faisal Specialist Hospital and Research Center during the period from March to July 2018. The local ethics committee approved the study in January 2018 (RAC number: 2180010).

2.2. Eligibility Criteria of the Study Population. Study subjects were consecutively selected according to the following criteria: (1) individuals with hemophilia A, (2) all individuals who are on Elocta® as a recombinant extended half-life coagulation factor product, and (3) individuals who have given informed consent. Individuals who developed inhibitor antibodies were excluded.

2.3. Laboratory Testing. Samples for measurement of FVIII activity were collected in citrated tube 3.2 for each patient at least two samples at 24 hrs from the dose and just before the next dose. Additional samples at 48, 72, 96, and 120 hrs after dose injection had been collected as part of another study for pharmacokinetics. The two methods used for measurement of FVIII activity were the clotting and chromogenic method. The clotting method uses an immune-depleted or deficient plasma (Sta®ImmunoDefVIII) by Stago Diagnostica STA®-Neoplastine® CI Plus and STA®-Unicalibrator which is intended for the determination of Factor VIII (anti-hemophilic A factor) activity in the plasma. The assay consists of the measurement of the clotting time in the presence of cephalin and activator of a system in which all the factors are present in excess, supplied by the deficient plasma reagent, except factor VIII which is derived from the sample being tested. On the other hand, the chromogenic method (TriniCHROM™ Factor VIII:C) by TCoag Stago Diagnostica, is designed to quantitatively determine Factor VIII:C in the human plasma, as well as the Factor VIII concentrate. Factor VIII:C is a plasma protein that exists with von Willebrand factor as a complex. After activation through thrombin, Factor VIII:C acts as a cofactor to convert Factor X to Factor Xa in the presence of calcium and phospholipids. The quantity of the generated Factor Xa is determined by means of a specific chromogenic substrate, and it is directly proportional to the Factor VIII:C amount in the sample.

2.4. Statistical Analysis. Categorical data were summarized as frequencies and percentages, while continuous data were presented as mean and standard deviation. For comparison of categorical and continuous variables, we used the Chi-square test and Student’ t-test, respectively. A discrepancy was defined as an FVIII:C ratio between the one-stage to the chromogenic assay of ≤0.6. The Spearman correlation coefficient was calculated to represent the correlation between the two assay measurements. An alpha level below 0.05 was considered for statistical significance. All analyses were performed using SPSS statistical software (version 25, for windows).

3. Results

3.1. Characteristics of the Study Population. Our study included 14 hemophilia A (11 severe and three moderate) patients with body weight ranged between (25 to 100) kg. Of them, 13 patients received Elocta® as a prophylactic treatment (25–40 U/kg two times weekly), and one patient received Elocta® on demand. One patient received Elocta®...
once a week, three patients received Elocta® twice a week, and eight patients received Elocta® every five days with one patient missing the frequency. The mean (SD) age of the study population was 23.9 (11.8) years. Our cut-off age for pediatric patients was 14 years; three patients were younger than 14 years (all three patients were at 10 years old), and 11 patients were older than 14 years.

3.2. The Discrepancy in FVIII : C between the One-Stage and Chromogenic Assays. Out of the 56 samples collected from 14 patients, 20 samples (35.7%) showed discrepancies (one-stage FVIII : C/Chromogenic FVIII : C ≤ 0.6), while 36 samples (64.3%) showed no significant differences. About 16 samples (28.5%) were identical.

3.3. The Overall Mean Difference in FVIII between One-Stage vs. Chromogenic Assays. In all samples (n = 56), there was a statistically significant difference between the measurement of factor VIII levels by the chromogenic and the one-stage assay using Student’ t-test (0.14 IU/mL and 0.08 IU/mL; $P < 0.001$). FVIII : C levels by the one-stage assay were lower than those measured by the chromogenic assay. The mean values of factor VIII levels measured by the two assays are shown in Figure 1.

3.4. The Difference between the Two Assays Stratified by Time since the Last Elocta® Dose. When the samples were sub-grouped according to the time interval since the previous Elocta® dose, the differences between the two assays were statistically significant using Student’ t-test (Table 1). In all samples, our results demonstrated a significant difference between both assays with a mean difference (mean difference = −0.6, $P < 0.001$).

3.5. The Difference between the Two Assays in Individual Patients. When the samples were sub-grouped for each subject separately, the differences between the chromogenic and one-stage assays were statistically significant in four out of the 14 patients using Student’ t-test (Table 2). These differences ranged from 0.002 to 0.19 IU/ml.

3.6. The Correlation between the Chromogenic and One-Stage Assays. There was a statistically significant Spearman correlation between the chromogenic and one-stage assays ($r = 0.918$, $P < 0.001$). The correlations between the two measures were statistically significant in 9 out of 12 patients (those who had more than two different samples). The correlation coefficient was positive in all cases except one patient and ranged from 0.3 to 1 with most cases (11/12) having a strong correlation between the two assay measures (Table 3). The line charts of the correlation between the two assays after one day, three days, and five days are shown in Figure 2.

3.7. Prediction of Plasma Factor VIII Levels after Injection by Time since the Last Injection. In this part, we took the total samples for each patient at 24, 48, 72, 96, and 120 days. Patients younger than 14 years were excluded. The time since the last injection was calculated and presented as the number of days. A linear regression analysis model was constructed. The linear regression model showed that the time interval since the last injection could significantly predict plasma factor VIII levels measured by the chromogenic assay ($\beta = 0.366$, $P < 0.001$). The regression equation from this model was Predicted plasma FVIII : C = -0.065 Time Interval since the Last Injection + 0.366.

Based on this regression equation, the plasma levels of factor VIII in adult patients with severe-to-moderate hemophilia A decrease to 0.01 IU/mL after 5.4 days since the last injection.

4. Discussion

4.1. Study Findings and Comparisons. Our study showed that the FVIII : C measured by chromogenic and one-stage assays was discrepant in 35% of the population. Although the FVIII : C levels measured by the one-stage assay were less than those estimated by the chromogenic assay, this difference was statistically significant in some individuals and not significant in others. Furthermore, a statistically significant difference was detected between both assays in all samples ($P < 0.001$). The difference between the chromogenic and the one-stage assay ranged from 0.002 to 0.19 IU/mL. Therefore, there was a strong correlation but not agreement between the chromogenic and the one-stage assay. This disagreement can be attributed to the genetic differences as proposed by Cid et al. [23] and Pavlova et al. [24]. Our regression analysis showed that, in adult patients with moderate-to-severe hemophilia A, the level of FVIII decreases to 0.01 IU/mL after about 5.4 days from the last Elocta® injection, highlighting that the prophylactic dose of Elocta® can be given up to every five days.

4.2. Previous Studies. Previous reports in the literature have shown discrepancies between the chromogenic and the one-stage assay in measuring FVIII : C [20]. The literature suggests that the discrepancies between the two assays occur in a substantial proportion of mild and moderate (nonsevere) hemophilia A patients [18, 21].

Cid et al. [23] studied the discrepancy between the chromogenic and the one-stage assays for the measurement of FVIII levels in 163 patients with hemophilia A. They detected discrepancies in 20% of the patients. Moreover, the mutations of FVIII were associated with either higher or lower levels of FVIII by the one-stage assay and normal levels of FVIII with the chromogenic assay, suggesting that the discrepancies might be due to genetic variations among individuals.

Another study by Pavlova et al. [24] showed that about one-third of the patients with nonsevere hemophilia A show discrepancies in FVIII levels when measured by the chromogenic and one-stage assays. Moreover, these discrepancies were attributed to genetic mutations. This finding is
consistent with our study, where 35% of the samples showed a discrepancy.

Kihlberg et al. [25] compared the two assays in 44 plasma samples from 35 hemophilia B patients; they found no discrepancies between the two measurements in the patients with severe hemophilia. However, among those with non-severe hemophilia, 15 samples showed at least a two-fold higher difference between the two assays with the one-stage assay presenting a lower value compared to the chromogenic assay. Moreover, 14 out of 15 of the discrepant samples belonged to individuals with genetic mutations exposing them to factor deficiency.

Potgieter et al. [18] showed that the results of both assays are well-correlated; however, the one-stage assay might be
influenced by nonspecific inhibition [18]. The one-stage assay might misestimate FVIII:C levels. Therefore, when used alone, it might lead to some misclassification of patients; the one-stage assay can show normal FVIII:C in hemophilia A patients while diagnosing normal FVIII:C people as hemophiliacs [18].

Moreover, a recent study showed the difference between the two assays with different incubation times. They found

| Patient ID | Age | N  | Correlation coefficient | P value |
|------------|-----|----|-------------------------|---------|
| Patient 1  | 25  | 5  | 0.97                    | 0.004   |
| Patient 2  | 24  | 4  | −0.802                  | 0.198   |
| Patient 3  | 57  | 4  | 1                       | <0.001  |
| Patient 4  | 32  | 5  | 0.38                    | 0.523   |
| Patient 5  | 28  | 5  | 0.996                   | <0.001  |
| Patient 6  | 24  | 4  | 1                       | <0.001  |
| Patient 7  | 10  | 1  | NA                      | NA      |
| Patient 8  | 30  | 5  | 0.993                   | 0.001   |
| Patient 9  | 26  | 2  | 1                       | <0.001  |
| Patient 10 | 34  | 5  | 0.991                   | 0.001   |
| Patient 11 | 36  | 7  | 0.994                   | <0.001  |
| Patient 12 | 29  | 5  | 0.994                   | 0.001   |
| Patient 13 | 10  | 3  | 0.999                   | 0.26    |
| Patient 14 | 10  | 1  | NA                      | NA      |

N = number of samples evaluated; NA = not applicable since one sample was available.

![Line charts](image-url)
that, in the chromogenic assay, FVIII:C levels were higher after incubation for 2 minutes than after 10 minutes, while in the standard coagulation assay, FVIII:C levels were higher at shorter incubation times than at longer incubation times usually used [26].

Some reports suggest that the chromogenic assay should be the routine practice in clinical laboratories as it is probably more suitable than one-stage clotting [19, 20]. While others recommend that both assays should be accessible in clinical laboratories [18], and laboratory scientists and clinicians should learn about the advantages and pitfalls of each assay so that they can select the suitable assays for each case and interpret them accurately [20].

4.3. Strength Points. The strong points of our study are as follows: (1) we analyzed the measurement differences in multiple samples from the same patients allowing the exploration of the correlation and discrepancies within the same patient, and (2) samples were taken at different time points, therefore, allowing the examination of the discrepancies at different time intervals since the last Elocta® injection. Nonetheless, our study is limited by the small sample size and the lack of information about the genetic mutations in the study’s population which might explain the measurement discrepancies between the two assays as reported in the literature.

4.4. Generalizability and Current Knowledge. This study expands the literature by confirming the discrepancies between the chromogenic and the one-stage assays for the measurement of FVIII:C in hemophilia A patients who are taking Elocta®.

5. Conclusions

The current findings of our study showed that the FVIII:C levels measured by the one-stage assay were less than those estimated by the chromogenic assay. However, the chromogenic and the one-stage FVIII assays are well correlated in this population. We recommend that, in Hemophilia A patients treated with Elocta®, the prophylactic dose can be given up to five days. Further studies on a larger sample are required to explore the correlation and agreement between both methods.

Data Availability

Data used to support the findings of this study are included within the supplementary information file(s).

Conflicts of Interest

The authors state that they have no conflicts of interest.

Authors’ Contributions

TMO and MS designed the research study. TMO, HAA, and MS contributed to patients recruitments. NSN and AOA contributed to the interpretation of the results. AMA contributed to sample preparation and biochemical analysis. All authors discussed the results and contributed to the final manuscript.

Acknowledgments

This study received initial support from Sobi for the purchase of reagents for chromogenic FVIII assay.

References

[1] K. Fijnvandraat, M. H. Cnossen, F. W. G. Leebeek, and M. Peters, “Diagnosis and management of haemophilia,” BMJ, vol. 344, Article ID e2707, 2012.
[2] L. W. Hoyer, “Hemophilia A,” New England Journal of Medicine, vol. 330, no. 1, pp. 38–47, 1994.
[3] P. H. Bolton-Maggs and K. J. Pasi, “Haemophilias A and B,” The Lancet, vol. 361, no. 9371, pp. 1801–1809, 2003.
[4] D. Umar, K. Baroudi, R. Kaul, and S. Shastry, “Hemophilia A: dental considerations and management,” Journal of International Society of Preventive and Community Dentistry, vol. 4, no. 6, p. 147, 2014.
[5] C. R. Rizza and J. M. Matthews, “Management of the haemophilic child,” Archives of Disease in Childhood, vol. 47, no. 253, pp. 451–462, 1972.
[6] B. Zimmerman and L. A. Valentinio, “Hemophilia: In review,” Pediatrics in Review, vol. 34, 2013.
[7] A. L. Dunn, “Hemophilia A,” in Transfusion Medicine and HemostasisElsevier, Amsterdam, Netherlands, 2009.
[8] M. Makris, J. Oldenburg, E. P. Mauser-Bunschoten, K. Peerlinck, G. Castaman, and K. Fijnvandraat, “The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH,” Journal of Thrombosis and Haemostasis, vol. 16, no. 12, pp. 2530–2533, 2018.
[9] V. S. Blanchette, N. S. Key, L. R. Ljung, M. J. Manco-Johnson, H. M. van den Berg, and A. Srivastava, “Definitions in hemophilia: communication from the SSC of the ISTH,” Journal of Thrombosis and Haemostasis, vol. 12, no. 11, pp. 1935–1939, 2014.
[10] P. Brywood, S. Newton, L. Mundy et al., “Evidence-based clinical practice guidelines for the use of recombinant and plasma-derived FVIII and FIX products,” Aust Heal Minist Advis Coun, vol. 254, 2006.
[11] S. C. Darby, D. M. Keeling, R. J. D. Spooner et al., “The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99,” Journal of Thrombosis and Haemostasis, vol. 2, no. 7, pp. 1047–1054, 2004.
[12] S. Ehrenforth, W. Kreuz, R. Linde et al., “Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs,” The Lancet, vol. 339, no. 8793, pp. 594–598, 1992.
[13] K. Gomez, R. Klamroth, J. Mahlangu et al., “Key issues in inhibitor management in patients with haemophilia,” Blood Transfus, vol. 12, no. Suppl 1, pp. S19–29, 2014.
[14] S. Sahu, S. Singh, I. Lata, and M. Kumar, “Revisiting haemophilia management in acute medicine,” Journal of Emergencies, Trauma, and Shock, vol. 4, no. 2, p. 292, 2011.
[15] X. Delavenne, E. Ollier, A. Lienhart, and Y. Dargaud, “A new paradigm for personalized prophylaxis for patients with severe haemophilia A,” Haemophilia, vol. 26, no. 2, pp. 228–235, 2020.
J. A. Abrantes, A. Solms, D. Garmann, E. I. Nielsen, S. Jönsson, and M. O. Karlsson, "Bayesian forecasting utilizing bleeding information to support dose individualization of factor VIII," CPT: Pharmacometrics & Systems Pharmacology, vol. 8, no. 12, pp. 894–903, 2019.

L. A. Valentino, P. L. Turecek, H. Gritsch, S. Butenas, and K. G. Mann, "Issues complicating precision dosing for factor VIII prophylaxis," Transfusion and Apheresis Science, vol. 57, no. 4, pp. 472–479, 2018.

J. J. Potgieter, M. Damgaard, and A. Hillarp, "One-stage vs. chromogenic assays in haemophilia A," European Journal of Haematology, vol. 94, no. Suppl 7, pp. 38–44, 2015.

A. Tripodi, V. Chantarangkul, C. Novembrino, and F. Peyvandi, "Advances in the treatment of hemophilia: implications for laboratory testing," Clinical Chemistry, vol. 65, 2018.

D. M. Adcock, K. Strandberg, M. Shima, and R. A. Marlar, "Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B," International Journal of Laboratory Hematology, vol. 40, 2018.

J. Oldenburg and A. Pavlova, "Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype," Hamostaseologie, vol. 30, no. 4, pp. 207–211, 2010.

E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies," Journal of Clinical Epidemiology, vol. 61, no. 4, pp. 344–349, 2008.

A. R. Cid, M. Calabuig, V. Cortina et al., "One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype," Haemophilia, vol. 14, no. 5, pp. 1049–1054, 2008.

A. Pavlova, D. Delev, B. Pezeshkpoor, J. Müller, and J. Oldenburg, "Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays," Thrombosis and Haemostasis, vol. 111, no. 5, pp. 851–861, 2014.

K. Kihlberg, K. Strandberg, S. Rosén, R. Ljung, and J. Asterman, "Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B," Haemophilia, vol. 23, no. 4, pp. 620–627, 2017.

S. E. Rodgers, E. M. Duncan, D. M. Barbulescu, D. M. Quinn, and J. V. Lloyd, "In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results," British Journal of Haematology, vol. 136, no. 1, pp. 138–145, 2007.